VRX Announcement Pleases Investors
LAVAL, CANADA - The share price of Valeant Pharmaceuticals (VRX) has been under intense selling pressure for well over a year due to a faulty business model that once exposed, sent the stock price into a seemingly never-ending tailspin. Now, the company is optimistic that its new drug will reverse the downward trend and give investors some much-needed confidence in the pharmaceutical company.
FDA Bullish On VRX
Some pharmaceutical analysts believe that Nobearashipan, a new drug awaiting FDA approval under Valeant's umbrella of medications, could send VRX back to the top of the sector.
"This drug is revolutionary," said Alethia Young, an analyst covering VRX for Credit Suisse. "From what I've read, Nobearashipan is going to be a HUGE winner."
Andrew Fein from HC Wainwright had a similar assessment after reviewing some preliminary data released today.
"You can never say for sure with Valeant," said Fein, "but this looks like an impressive feat by the company. The drug has blown through all the required landmarks, and from my perspective, is ready to go. FDA approval is imminent."
Make Valeant (VRX) Great Again
Valeant CEO Joseph Papa was on hand to speak about his company's fight back to the top.
"I wasn't in charge when the ship capsized," said Papa, "but I'm doing everything in my power to reward our investors for their patience. Nobearashpan is the first of its kind. It works on the ocular nerves and the visual cortex to produce incredible results. I shouldn't say this, but I've taken two of them today and the outlook for our company could not be better!"
Papa went on to say that the final phase concluded this week as investors in DryShips (DRYS) were administered the drug over past couple of weeks.
Dr. Oz Reviews VRX Data
To demonstrate their seriousness in selling Nobearashpan to investors, the brass at VRX called on Dr. Oz to review the data of the study, which simultaneously included all three phases.
"What an outstanding drug," said Dr. Oz. "When you take it, your optic nerves become incapable of recognizing sinking stock prices. So even at under $14 a share, VRX looks as good as gold. For people who are anxious or depressed about their investment, just take two of these beauties and you'll be feeling bullish immediately. The future will look bright again!"